TIDMCOG

RNS Number : 3870A

Cambridge Cognition Holdings PLC

02 February 2022

Cambridge Cognition Holdings Plc

("Cambridge Cognition" or the "Company")

Cambridge Cognition wins GBP2.1 million contract to provide digital assessments for two neurodegenerative disease clinical trials

Cambridge Cognition Holdings Plc (AIM: COG), which develops and markets digital solutions to assess brain health, is pleased to announce that it has been awarded contracts worth GBP2.1 million to provide cognitive assessments, electronic diaries, and third-party hardware for two clinical trials in neurodegenerative disease. Revenue is expected over the next three financial years.

Neurodegenerative disease represents a major global medical need. If treatments are not developed soon, then it is estimated that more than 12 million Americans will be living with neurodegenerative diseases by 2050(1) . Cognitive dysfunction is a hallmark of many neurodegenerative diseases and so sensitive and specific cognitive assessment are essential in developing effective treatments. With unrivalled use in over 2,500 peer-reviewed publications, Cambridge Cognition's digital cognitive assessments offer customers outstanding sensitivity and specificity.

A US biotechnology company that has worked with Cambridge Cognition previously is investigating the effect of a new drug in two neurodegenerative diseases. With some data being collected in clinic and further insights taken at home, these two clinical trials are being run in a hybrid or part-virtual manner.

Cambridge Cognition has been contracted to deliver both elements: providing gold-standard, computerized cognitive assessments (CANTAB(TM) ) for use in clinics, as well as daily tests of cognition and a patient diary to track other symptoms via a mobile app. This blend of in-clinic and at home monitoring can provide much more detailed insights into the development of disease over time and the efficacy of new pharmaceutical compounds. The electronic diaries for the trials are being provided using the Company's electronic Clinical Outcomes Assessment (eCOA) platform. The Company is also providing third party hardware for use in clinics and at home.

Matthew Stork, Chief Executive Officer of Cambridge Cognition, said:

"We are delighted to have secured these sizeable contracts with an existing client as they progress with further clinical trials of their new drug. They already have an experience of CANTAB(TM) and so it is also excellent news that our team have been successful in demonstrating the value of both our daily cognitive tests and our eCOA platform, and with it considerably increasing the value of the contracts."

References

   1.        Harvard NeuroDiscovery Center. https://neurodiscovery.harvard.edu/challenge

For further information, contact:

 
 Cambridge Cognition Holdings Plc                      Tel: 012 2381 0700 
  Matthew Stork, Chief Executive Officer                press@camcog.com 
  Sally Jennings, Head of Marketing & Communications 
 finnCap Ltd (NOMAD and Joint Broker)                  Tel: 020 7220 0500 
  Geoff Nash / Simon Hicks                              (Corporate Finance) 
  Alice Lane / Charlotte Sutcliffe                      (Corporate Broking) 
 Dowgate Capital Limited (Joint Broker)                Tel: 020 3903 7715 
  David Poutney / James Serjeant 
 IFC Advisory Ltd (Financial PR and IR)                Tel: 020 3934 6630 
  Tim Metcalfe / Graham Herring / Zach Cohen

Notes to Editors

About Cambridge Cognition

Cambridge Cognition is a technology company developing digital health products to better understand, detect and treat conditions affecting brain health. The Company's software products assess cognitive health in patients worldwide to improve clinical trial outcomes, identify and stratify patients early and improve global efficiency in pharmaceutical and healthcare industries.

For further information visit www.cambridgecognition.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

CNTTBMPTMTBMBTT

(END) Dow Jones Newswires

February 02, 2022 01:59 ET (06:59 GMT)

Cambridge Cognition (LSE:COG)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024 Haga Click aquí para más Gráficas Cambridge Cognition.
Cambridge Cognition (LSE:COG)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024 Haga Click aquí para más Gráficas Cambridge Cognition.